Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL9366683 | 0.86 | TSHR (0.69) | TSHRNAPRTTDP1CHRM5CHKA | |
| Pyridine SCHEMBL27925045 | 0.83 | TSHR (0.64) | TSHRNAPRTTDP1CHRM5CHKA | |
| Pyridine SCHEMBL27499168 | 0.83 | TSHR (0.64) | TSHRNAPRTTDP1CHRM5CHKA | |
| Pyridine SCHEMBL1066444 | 0.82 | TSHR (0.75) | TSHRNAPRTTDP1KMT2ANOTUM | |
| Pyridine SCHEMBL27737222 | 0.82 | TSHR (0.75) | TSHRNAPRTTDP1KMT2ANOTUM | |
| Pyridine SCHEMBL3627909 | 0.82 | — | — | |
| Pyridine SCHEMBL14892921 | 0.80 | TSHR (0.60) | TSHRNAPRTTDP1CHRM5CHKA | |
| Pyridine SCHEMBL21758532 | 0.80 | TSHR (0.60) | TSHRNAPRTTDP1CHRM5CHKA | |
| Pyridine SCHEMBL28805835 | 0.80 | TSHR (0.60) | TSHRNAPRTTDP1CHRM5CHKA | |
| Pyrimidine SCHEMBL7866761 | 0.80 | TSHR (0.33) | TSHRNAPRTTDP1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3360869-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND USEFUL FOR THE TREATMENT OF DISEASES CAUSED BY LPA. | UBE INDUSTRIES (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2940013-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2940013-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2212300-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009053459-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| US-4200726-A | Semipermeable membrane of phenoxy resin containing sulfuric acid groups or salts thereof | DAICEL LTD. (JP) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | TSHR 42/4885NAPRT 1227/4885TDP1 3881/4885 |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | LPAR1, LPAR4, LPAR2 | TSHR 59/4885NAPRT 740/4885TDP1 3634/4885 |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | TSHR 42/4885NAPRT 1227/4885TDP1 3881/4885 |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | LPAR3, LPAR1, LPAR2 | TSHR 42/4885NAPRT 1227/4885TDP1 3881/4885 |
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX3, P2RX2 | TSHR 475/4885NAPRT 1597/4885TDP1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.